Extending in vitro digestion models to specific human populations: Perspectives, practical tools and bio-relevant information by Shani-Levi, Carmit et al.
 
Document downloaded from: 
 

























Shani-Levi, C.; Alvito, P.; Andrés Grau, AM.; Assunção, R.; Barbera, R.; Blanquet-Diot, S.;
Bourlieu, C.... (2017). Extending in vitro digestion models to specific human populations:






EXTENDING IN VITRO DIGESTION MODELS TO SPECIFIC HUMAN 1 
POPULATIONS: PERSPECTIVES, PRACTICAL TOOLS AND BIO-RELEVANT 2 
INFORMATION 3 
Carmit Shani Levia, Paula Alvitobc, Ana Andrésd, Ricardo Assunçãobc, Reyes Barberáe, 4 
Stéphanie Blanquet-Diotf, Claire Bourlieug, André Brodkorbi, Antonio Cillae, Amélie 5 
Deglaireh, Sylvain Denisf, Didier Duponth, Ana Herediad, Sibel Karakayaj, Concetta 6 
Valeria Lucia Giosafattok, Loredana Mariniellok, Carla Martinsbc, Olivia Ménardh, Sedef 7 
Nehir Elj, Gerd Elizabeth Vegarudl, Ellen Ullebergl, and Uri Lesmesa * 8 
 9 
aDepartment of Biotechnology and Food Engineering, Technion – Israel Institute of Technology, Haifa, 10 
Israel 11 
 bFood and Nutrition Department, National Institute of Health, Lisbon, Portugal  12 
cCESAM, Centre for Environmental and Marine Studies, University of Aveiro, Portugal 13 
d Institute of Food Engineering for Development, Universitat Politècnica de València, Valencia, Spain 14 
eFaculty of Pharmacy. University of Valencia, Valencia, Spain 15 
fEngineering and Development of Food and Drug, University of Auvergne, Clermont-Ferrand, France. 16 
g IATE 1208, INRA, CIRAD, SupAgro, Montpellier, France 17 
hSTLO Agrocampus Ouest, INRA, Rennes, France  18 
i Teagasc Food Research Centre, Cork, Ireland 19 
j Food Engineering Department, Ege University, İzmir, Turkey 20 
kDepartment of Chemical Sciences, University of Naples Federico II, Naples, Italy 21 
lNorwegian university of Life Sciences, As, Norway 22 
 23 
* Corresponding Author:  Assistant Prof. Uri Lesmes  24 
Laboratory of Chemistry of Foods and Bioactives 25 
Department of Biotechnology and Food Engineering,  26 
Technion – Israel Institute of Technology, Haifa 32000,  27 
Israel 28 
Tel. 972-77-8871869;  Fax.972-4-8293399 29 
Email: lesmesu@bfe.technion.ac.il 30 
 31 
Submitted to:   Trends in Food Science and Technology, Special issue 32 
Revision date:  October 2016 33 




Background. In vitro digestion models show great promise in facilitating the rationale 36 
design of foods.  This paper provides a look into the current state of the art and outlines 37 
possible future paths for developments of digestion models recreating the diverse 38 
physiological conditions of specific groups of the human population.  39 
Scope and Approach. Based on a collective effort of experts, this paper outlines 40 
considerations and parameters needed for development of new in vitro digestion models, 41 
e.g. gastric pH, enzymatic activities, gastric emptying rate and more. These and other 42 
parameters are detrimental to the adequate development of in vitro models that enable 43 
deeper insight into matters of food luminal breakdown as well as nutrient and 44 
nutraceutical bioaccessibility. Subsequently, we present an overview of some new and 45 
emerging in vitro digestion models mirroring the gastro-intestinal conditions of infants, 46 
the elderly and patients of cystic fibrosis or gastric bypass surgery.  47 
Key Findings and Conclusions. This paper calls for synchronization, harmonization and 48 
validation of potential developments in in vitro digestion models that would greatly 49 
facilitate manufacturing of foods tailored or even personalized, to a certain extent, to 50 
various strata of the human population. 51 
Key words: Food digestion, In vitro digestion, gastric, infants, elderly, Gastro-Intestinal 52 
disorders 53 
Abbreviations: CF-Cystic Fibrosis; EFFoST-European Federation of Food Science and 54 
Technology; GBP-Gastric Bypass; GI-Gastrointestinal; GIT-Gastrointestinal tract; IBD-55 
inflammatory bowel disease; IVD- In vitro digestion; PTL:Pancreatic Triglyceride 56 
Lipase; SG: Sleeve Gastrectomy 57 
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1. Introduction 58 
1.1 In vitro models for food research 59 
In vitro digestion (IVD) modelling is a vivid field of research that shows great promise in 60 
facilitating the development of foods and oral formulations based on better understanding 61 
of their digestive fate in the stomach and small intestine in as well as downstream 62 
ramifications to the gut microbiome(Bornhorst, Gouseti, Wickham, & Bakalis, 2016; 63 
Guerra, et al., 2012; Hur, Lim, Decker, & McClements, 2011; Payne, Zihler, Chassard, & 64 
Lacroix, 2012). Although human or in vivo animal studies are still considered a “gold 65 
standard” for tackling issues of bioaccessibility, absorption, bioavailability, metabolism 66 
and excretion, IVD methods have the advantage of being more rapid, less labor intensive 67 
and having significantly less bioethical restrictions. In fact, various IVD models have 68 
been increasingly applied to assess the digestive fate and potential toxicity of ingested 69 
natural and engineered nano-materials(Lefebvre, et al., 2015). This has led to great 70 
variability in scientific efforts, including some contradicting studies, and stimulated the 71 
recent effort of the INFOGEST network of scientists to develop a consensus harmonized 72 
static in vitro digestion model based on physiologically relevant conditions gathered from 73 
humans(Minekus, et al., 2014).  This harmonized protocol was validated in a wide inter-74 
laboratory trial(Egger, et al., 2016) and is currently pending on-going efforts to correlate 75 
findings of protein digestibility with an in vivo trial in pigs and biochemical assays with 76 
human aspirates (yet to be published). However, these and other numerous scientific 77 
publications focus on IVD systems designed for evaluating the digestive fate of foods and 78 
oral formulations in the adult alimentary canal.   79 
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During a dedicated workshop held by the European Federation of Food Science and 80 
Technology (EFFoST) in Athens on November 2015, we found that current physiological 81 
literature offers professionals additional opportunities to recreate the unique and specific 82 
gastro-intestinal (GI) functions of other human populations, such as infants, the elderly 83 
and more. Such intriguing possibilities would open new opportunities to study and 84 
develop foods and oral formulations better tailored to the needs of such specific 85 
populations. Based on the pooled and accumulated experience of the INFOGEST 86 
network, it was decided to help a systematic and responsible orchestration of relevant 87 
global efforts, maximize synergisms between researchers and harmonize efforts to 88 
develop new IVD models. Thus, this paper provides a look into the current state of the art 89 
and paves possible future paths for developments, all with the aim of ensuring adequate 90 
and fruitful endeavors and outputs to the food and health community. 91 
1.2 Current status of adult in vitro digestion (IVD) models  92 
In vitro digestion models were initially developed to serve as research tools to 93 
characterize and clarify the structural and biochemical changes of food components under 94 
physiological conditions, caused by alimentary enzymes, GI motility and by the colonic 95 
microbiota. In principle, IVD models of the upper GI need to overcome the shortcomings 96 
of in vivo trials (i.e. ethical constraints, low throughput, control over subjects and 97 
reproducibility) and account for the most bio-relevant anatomical and physiological 98 
considerations mirroring the mouth, stomach, small and large intestine lumen and gut 99 
lining. In fact and in spite of their limitations, IVD models are particularly suited for 100 
investigating the luminal physiochemical changes in food, matters of bioaccessibility and 101 
some aspects of bioavailability.  102 
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Historically, efforts to develop IVD models began in the early 1990's with pioneering 103 
works to develop reliable, robust, reproducible and bio-relevant tools like the multi-104 
compartmental GI model developed by TNO in the Netherlands(Minekus, Marteau, 105 
Havenaar, & Huisintveld, 1995) or the three stage continuous fermentation systems 106 
recreating the human colon(Macfarlane, Macfarlane, & Gibson, 1998; Molly, Woestyne, 107 
& Verstraete, 1993). Since, the field has boomed with numerous IVD models, ranging 108 
from simple static mono-compartmental models to computer-controlled multi-109 
compartmental dynamic IVD models, as reviewed by others (Glahn, Wien, VanCampen, 110 
& Miller, 1996; Guerra, et al., 2012; Hur, et al., 2011; McClements & Li, 2010; Payne, et 111 
al., 2012; Yoo & Chen, 2006). Recent studies even raised the possibility of using human 112 
GI aspirates in IVD models (Ulleberg, et al., 2011) or coupling IVD models with human 113 
cell cultures of Caco-2 epithelial cells or Caco-2 co-cultures with HT-29 mucus 114 
producing cells (Emmanuelle Deat, et al., 2009; E. Deat, et al., 2009; Vors, et al., 2012). 115 
Yet, the low accessibility and stability of human aspirates and the complexity of coupling 116 
IVD research with cell cultures, challenge the wide spread use of highly bio-relevant 117 
alternatives over simple protocols currently used in IVD models. Further, in vitro cell 118 
culture systems have been coupled to some IVD models to enable investigating questions 119 
of cellular uptake and brush border enzymatic breakdown, which better elucidate the 120 
bioavailability of specific substances(Emmanuelle Deat, et al., 2009; E. Deat, et al., 2009; 121 
Manione, et al., 2015; Vors, et al., 2012).  122 
Concomitantly, various efforts reported to develop and apply sophisticated IVD models 123 
that are intended to be more realistic, encompassing various aspects of digestion 124 
dynamics (e.g. physiological acid secretion and gastric emptying), mass transport 125 
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phenomena (i.e. absorption and diffusion) and rheological aspects (i.e. mixing) (Blanquet, 126 
et al., 2004; Dekkers, Kolodziejczyk, Acquistapace, Engmann, & Wooster, 2016; Kong 127 
& Singh, 2010a; Levi & Lesmes, 2014; Mercuri, Lo Curto, Wickham, Craig, & Barker, 128 
2008; Shani-Levi, Levi-Tal, & Lesmes, 2013; Tharakan, Norton, Fryer, & Bakalis, 2010; 129 
Yoo & Chen, 2006).  To date, both advanced and simple IVD models have be used to 130 
investigate a variety of systems. Examples include investigations of simple high purity 131 
protein solutions, multi-component model systems like emulsions and even more real 132 
foods, like dairy gels and pasta. These and other investigations have significantly 133 
advanced our understanding of the interplay between food ingredients, food products and 134 
the alimentary canal of healthy adults. Such insights include not just understanding of 135 
food breakdown but also its impact on gastro-intestinal functions, e.g. gastric emptying 136 
and intestinal motility, as detailed by others (Grundy, et al., 2016; Houghton, Hickson, & 137 
Read, 1987; Meyer, Elashoff, & Lake, 1999; Sarosiek, et al., 2010). 138 
Identified research needs. Despite the various hectic activity in the field of 139 
understanding food's digestion in adults, there is still much room for further 140 
advancements and breaching of current gaps in knowledge and capabilities.  The various 141 
discussions held during the Athens workshop identified that amongst future 142 
advancements in the field, research should include efforts: [I] To improve the bio-143 
relevance of luminal composition and dynamics (e.g. pH profiles and use of gastric 144 
lipases); [II] To validate and/or correlate IVD data with in vivo findings; [III] To recreate 145 
the 3D micro-architecture of the intestinal lining and mucosa through co-cultures (e.g. 146 
Caco-2 and HT29 cell lines, grown on various scaffolds); and  [IV] To develop predictive 147 
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in silico models. All of these topics were enthusiastically discussed in separate work 148 
groups during the workshop and are expected to bring up further scientific publications.   149 
1.3 Rationale and approach for extending IVD models 150 
Advancements in the field of food science and technology need to address numerous 151 
challenges that humanity is and will be facing in the 21 century(Floros, et al., 2010). 152 
These challenges will include feeding the growing and ageing world population, better 153 
and sustainable use of natural resources as well as improving our ability to exploit foods' 154 
potential to prevent diseases and maintain health promote wellness. In this respect, 155 
personalized or tailored nutrition seem highly promising and challenging strategies 156 
(Joost, et al., 2007; Qi, 2014; Zeevi, et al., 2015). Such endeavors will require bridging 157 
manufacturing capabilities and product engineering to meet the specific needs of the 158 
consumer. Based on the demonstrated success in the field of infant formula development, 159 
IVD models harbor great potential to facilitate relevant developments of foods tailored to 160 
thespecific GI capabilities of specific human starta such as elderly people, pregnant 161 
women, patients of various Inflammatory  Bowel Diseases (IBD) and even diabetics.    162 
Thus, this paper outlines the considerations and parameters needed for development of 163 
new IVD models as well as an overview of some of the new and emerging IVD models 164 
and the relevant physiological information, all with the aim of stimulating adequate and 165 
fruitful endeavors and outputs to the food and health community. Adapting the consensus 166 
INFOGEST protocol scheme, a basic static model is suggested to comprise of an oral, 167 
gastric and intestinal phase(Minekus, et al., 2014). Each phase should address the 168 
composition of the relevant simulated fluid (ionic and enzymatic composition), the time 169 
of processing and the nature of the bolus/chyme (liquid, semi-solid or solid and dilution 170 
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ratio with the bodily secretions). The selection of the quantitative aspects for the 171 
operational parameters should rely on information gathered from the most relevant 172 
human studies with good statistical power (i.e. avoiding studies with less than 10 subjects 173 
as a rule of thumb). In circumstances where no human data can be found, developers 174 
should either make their best effort to rationally approximate the values or attempt to 175 
determine them directly as a part of a human trial. Thus, any new IVD model should 176 
clearly define its parameters, justify their selection and support it with relevant 177 
references.   178 
2. Practical considerations for developing IVD models 179 
Human GI physiology is a complicated semi-continuous set of bioreactors that are 180 
intertwined with the hematological, hormonal and nervous systems and change during 181 
life(L R Johnson, 2007; Remond, et al., 2015; Tortora & Derrickson, 2011). This highly 182 
complex nature of the GI limits the ability to recreate its entire functions in an in vitro 183 
model. However, many aspects of luminal digestion can be mirrored in IVD models using 184 
reliable and detailed information on the digestive system that can be found in the 185 
scientific literature. Therefore, it is imperative to understand the limitations of each 186 
model and ensure they do not collide with the research hypotheses. To this end, it is also 187 
imperative to be aware of and address the key anatomical and physiological parameters of 188 
the relevant GI organs.    189 
The process of food digestion is an orchestrated series of bioprocessing operations that 190 
involve the breakdown of food, the release of nutrients, their uptake or downstream 191 
fermentation before their ultimate removal from the body through defecation. During 192 
digestion in the upper GI, food structure is broken down in the mouth, stomach and small 193 
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intestine through complex reactions and interactions involving chemical and mechanical 194 
processes (Ferrua & Singh, 2010; L R Johnson, 2007; Sensoy, 2014). Therefore, the 195 
following section discuss the most critical physiological parameters that are essential for 196 
in vitro digestion models. 197 
2.1. Oral phase  198 
Oral processing involves mastication and mechanical breakdown of food into a soft mass, 199 
termed bolus which is a mixture of processed food and saliva(DeSesso & Jacobson, 200 
2001). This short phase is detrimental to the sensorial perception of food and can be 201 
viewed as a coarse mechanical processing step with little chemical changes(Aken, 202 
Vingerhoeds, & Wijk, 2011; van Vliet, van Aken, de Jongh, & Hamer, 2009). This first 203 
step of digestion involves mixing food with salivary fluid that contains about 99% water 204 
in addition to various electrolytes and proteins, including enzymes such as amylase(Aps 205 
& Martens, 2005; Rantonen, 2003). Saliva is continuously secreted into the oral cavity by 206 
parasympathetic control. While resting, the flow rate is about 0.5 ml/min; but upon 207 
stimulation, the secretion increases 3 to 4- fold with maximal flow rates of 10 208 
ml/min(AC, 1991b). Healthy adults will produce 500–1500 ml saliva per day(Aps & 209 
Martens, 2005). Salivary fluid composition depends on the flow rate: at higher flow rates, 210 
sodium, calcium, chloride, bicarbonate, amylase increase while phosphate and mucin 211 
concentrations decrease, and the potassium concentrations show little change. Salivary 212 
pH values also fluctuate between fasted to fed state with values of 6.2-7.4 to 7.4-7.6, 213 
respectively(C. H. M. Versantvoort, Van de Kamp, E. and Rompelberg, C.J.M., 2004). 214 
The key salivary enzyme is α-amylase that hydrolyzes starch and related α-(1,4)-linked 215 
polysaccharides(Nagler & Hershkovich, 2005; Shern, Fox, & Li, 1993). Mucin is also an 216 
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important component of saliva with studies indicating it to induce emulsion 217 
flocculation(Sarkar, Goh, & Singh, 2009, 2010; Singh & Ye, 2013; Vingerhoeds, Silletti, 218 
de Groot, Schipper, & van Aken, 2009). Yet, commercial mucins are partially hydrolyzed 219 
mixtures of mammalian mucins which limit their bio-relevance when applied in IVD 220 
models.  In addition, there is some debate on the possible existence and activity of lingual 221 
lipase with a report indicating lingual lipase is active between pH 2-6.4, indicating that 222 
this enzyme is active from the mouth to the small intestine(Hamosh, 1994).  223 
2.2 Gastric phase  224 
Following bolus formation in the oral phase, the stomach further processes the bolus into 225 
a semi-solid chyme within four distinct regions: cardiac, fundic, body and the pyloric 226 
regions (Ferrua & Singh, 2010; Kong & Singh, 2010b). Gastric juice comprises of 227 
hydrochloric acid, enzymes (pepsin and gastric lipase), various electrolytes, mucus, 228 
intrinsic factor and hormones with approximately 2 L of gastric juice secreted daily and 229 
0.7 L secreted after a typical meal(Kopf-Bolanz, et al., 2012; Seeley, Stephens, & Tate, 230 
1992). Parietal cells lining the stomach wall are responsible for the secretion of 231 
hydrochloric acid into the gastric lumen and bicarbonate into the bloodstream. The 232 
activity of these cells is responsible for the unique pH of the stomach which dynamically 233 
changes during digestion from 1.5-2.0 in the fasted state to 3.0-7.0 in the fed state. 234 
Gastric acidity induces protein denaturation and precipitation, hydrolytic reactions (e.g. 235 
breakdown of starch) and significantly reduces bacterial counts in the gastric lumen.  The 236 
post-prandial pH rise in the stomach is attributed to the buffering capacity of the ingested 237 
food and the Parietal cells generate a pH gradient that over the course of time reverts 238 
luminal pH back to the fasted state values. The pH profiles depend on age and clinical 239 
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conditions of the consumer (Table 1) and can have various ramifications to the properties 240 
of ingested food systems, such as emulsions and gels(Dekkers, et al., 2016; Shani-Levi, et 241 
al., 2013). Gastric lipolysis and proteolysis are tightly linked(AC, 1991b; Sams, Paume, 242 
Giallo, & Carriere, 2016). The key gastric proteolytic enzyme, pepsin, is activated from 243 
its precursor pepsinogen (secreted by chief cells) via acid hydrolysis. The activated 244 
enzyme, which is also equated with commercial porcine pepsin, has a wide range of 245 
activity with optimal activity at pH 2 and inactivate just above pH 6.5(Johnston, Dettmar, 246 
Bishwokarma, Lively, & Koufman, 2007). Pepsin is a non-specific protease and therefore 247 
hydrolyses itself (a reaction termed auto-pepsinolysis) and other enzymes present in the 248 
lumen. Another gastric enzyme is gastric lipase which is also activated by the acidic 249 
environment in the stomach(Sams, et al., 2016). Gastric lipase presents sn-3 250 
regiospecificity thus it hydrolyses triglycerides into sn-1,2diglycerides and one free fatty 251 
acid, pancreatic triglyceride lipase colipase dependent which is sn-1,3 regioselective 252 
lipase (Miled, et al., 2000). However, commercial gastric lipase is hard to find and is 253 
currently neglected in many IVD models, thought it initiates lipolysis and release free 254 
fatty acids which activate pancreatic triglyceride lipase. 255 
The pyloric sphincter controls gastric emptying into the small intestine and is affected by 256 
three major factors: volume of the meal, its osmotic pressure and caloric content. 257 
Approximately 2 kcal/per minute are delivered through the pylorus to the 258 
duodenum(Campbell, 2015; Sams, et al., 2016). Furthermore, gastric emptying has been 259 
well described by the Elashoff equation (Elashoff, Reedy, & Meyer, 1982).   260 
  261 
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2.3 Small intestinal phase  262 
Gastric chyme is gradually emptied into the small intestine, where most of the chemical 263 
breakdown and absorption occur mediated by auxiliary secretions of the liver, gall 264 
bladder, pancreas and intestinal epithelia. Chyme entering from the stomach to the small 265 
intestine are neutralized using bicarbonate and the pH increases from 2 to 6.2 in the 266 
duodenum, which is the first segment of the small intestine(Kalantzi, et al., 2006). The 267 
main degradation of food starts in the duodenum into which about 1.2-1.5 L of pancreatic 268 
juice is secreted daily(L.R.  Johnson, 2007). The jejunum and ileum are the later sections 269 
of the small intestine where digestion and absorption are completed before indigested 270 
fractions are pushed into the colon. Due to the anatomical complexity of the small 271 
intestine one cannot easily find data on food digestion in these segments. The pancreatic 272 
juice contains a mixture of enzymes, proenzymes, protease inhibitors, sodium bicarbonate 273 
and other electrolytes that are secreted in parallel and gradually over the course of 3-4 274 
hours, depending on the meal ingested. The pancreatic secretions contain a variety of 275 
enzymes in their pro-enzyme forms and include protrypsin, prochymotrypsin, proelastase, 276 
procarboxypeptidases, pancreatic lipase and α-amylase in addition to ribonuclease and 277 
deoxyribonuclease(Boivin, Lanspa, Zinsmeister, Go, & Dimagno, 1990; Keller & Layer, 278 
2005). Currently, IVD models make use of ill-defined mixtures of pancreatin or concoct 279 
enzyme mixtures mainly containing trypsin and α-chymotrypsin.  Every day, the human 280 
liver produces about 0.6-1.0 L of bile, which are stored in the gallbladder(Seeley, et al., 281 
1992). Bile acids are steroid acids composed mainly from taurocholic acid, glycocholic 282 
acid, taurochenodeoxycholic acid and  glycochenodeoxycholic acid which are equal in 283 
concentration(Hofmann, 1999).  In addition to enzymes delivered into the lumen, 284 
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enzymes located in the epithelial brush border contribute to the further digestion of food. 285 
The brush border enzymes include glycosidases (dextrinase, glucoamylase), peptidases 286 
(aminopeptidase, carboxypeptidase, dipeptidase) and phophatases(Holmes & Lobley, 287 
1989). Altogether, the functions of the auxiliary organs in the fasted and fed conditions 288 
are stimuli responsive and are mainly affected by the composition of the ingested meal 289 
and the physical state of the consumer.  Unfortunately, a wide range of enzyme outputs 290 
and activities (units) are reported due to different focus of the studies; type of diet 291 
(calories), specific nutrient (lipid, carbohydrate, protein or minerals) or non-nutrients 292 
(pharmaceuticals, drugs etc.) and physical properties of the meal(Armand, et al., 1996; 293 
O'Keefe, et al., 2003). Further, there are inconsistencies in data on the pancreatic enzyme 294 
activities due to the differences in biochemical assays used to characterize these 295 
secretions: ranging from use of natural or synthetic standards such as casein, BAEE, 296 
TAME, BTEE, measurement modes (potentiometric, colorimetric, spectrophotometric), 297 
calculation methods up to the definition of enzymatic units of activity. Examples for 298 
values found in literature are summarized in Table 1. Mechanically, the small intestine 299 
has a segmented nature of pushing chyme further down the GI and this segmentation 300 
motion was recently shown to be critical for luminal mixing and mass transfer (Tharakan, 301 
et al., 2010). 302 
As denoted, the small intestine is the major site of absorption of small molecules, which 303 
can occur passively through diffusion or actively through various transporter systems in 304 
the gut wall(L R Johnson, 2007). Further processing of materials can then take place 305 
within epithelia, e.g. lipid packing into chylomicrons. Transit time through the small 306 
intestine varies according to the diet caloric density; the rheological/mechanical 307 
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properties (e.g. viscosity or gelling) and with consumer parameters, such as age and 308 
health (e.g. 2h for healthy adult and 3h for infant(Blanquet, et al., 2004)).   309 
2.4 Large intestinal phase  310 
Undigested and un-absorbed foodstuffs and bodily secretions transit into the large 311 
intestine through the ileocecal valve. In this last part of the human GI tract, water and 312 
electrolytes are re-absorbed and bacterial fermentation of fiber and un-digestible food 313 
components occurs before bulk material is excreted(Moran & Jackson, 1992). The colon 314 
is increasingly recognized for its milieu of bacteria, fungi, protozoa and archaea and rich 315 
metabolic activity equated to that of the human liver(Nardone & Malfertheiner, 2011; 316 
O'Hara & Shanahan, 2006; Olszewska & Jagusztyn-Krynicka, 2012; Turnbaugh, et al., 317 
2007). Recent studies of the human colon microbiome have established various links 318 
between nutrition, the microbiome and health with evidence that microbiomes are 319 
affected by age, gender, diet, culture, geography and various physiological/pathological 320 
states(Albenberg & Wu, 2014; D'Argenio, et al., 2013; Flint, 2012; Holscher, et al., 2015; 321 
Olszewska & Jagusztyn-Krynicka, 2012). Therefore, it is no surprise that the field of IVD 322 
models of the human colon are also a vibrant field, as reviewed by others(Payne, et al., 323 
2012). In essence, the colon hosts immense bacterial counts in three distinct loci: the 324 
proximal, transverse and distal colon, which vary in their steady state pH with values of 325 
5.8, 6.2 and 6.8, respectively with transit times of 12-36h. Metabolically, the microbiome 326 
is highly active with both glycolytic and proteolytic activities noted and about 90% of 327 
fermented indigestible polysaccharides being metabolized into short-chain fatty acids. In 328 
addition, the mucosa lining of the colon is a major site for passive absorption of small 329 
metabolites and close interactions with the immune system(Clemente, Ursell, Parfrey, & 330 
Knight, 2012). 331 
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3. IVD models for specific populations  332 
3.1. Infants 333 
The functionality of human gastro intestinal tract (GIT) develops in the first year of life 334 
with newborns (< 28 days of life) and infants up to six months possessing an immature 335 
digestive system compared to older infants (>6 months) or the fully mature GI of an adult 336 
(Figure 1). Moreover, prematurity affects strongly the digestive capabilities, with 337 
decreased GI functionality in preterm babies compared to full-term newborns(J Bruce, 338 
2012; D. Kelly & Coutts, 2000; E. J. Kelly & Newell, 1994; Ménard, Monfils, & 339 
Tremblay, 1995).  In fact, there are various differences between infants and adults mainly 340 
in some digestive enzymes and a relatively elevated gastric pH (3.5-6.5), as exhaustively 341 
reviewed(Abrahamse, et al., 2012; Bourlieu, et al., 2014; T. T. Nguyen, Bhandari, 342 
Cichero, & Prakash, 2015a, 2015b). Briefly, infant digestion process neglects oral phase 343 
due to liquid meals rapidly transiting through the oral cavity (5-10 sec). Small stomach 344 
storage capacity, affecting meal frequency, transit and volume, increases quickly during 345 
the first month of life from 10-20 mL up to 90-150 mL per meal(Abrahamse, et al., 2012; 346 
Bourlieu, et al., 2014). Infant fasting gastric pH is less acidic than of an adult 347 
(respectively 4-5 vs. 2 in the fasted state) which may change gastric proteolysis, as 348 
optimal activity of pepsin is 1.5-2.2(Henderson, Hamosh, Armand, Mehta, & Hamosh, 349 
1998; Li-Chan & Nakai, 1989; Schlamowitz & Peterson, 1959). Reduced pepsin 350 
secretion in newborns, 10-20% from adult levels, is another physiological reason 351 
explaining the limited gastric proteolysis (15%) reported for infants(Bourlieu, et al., 352 
2014; Didier Dupont, et al., 2010; Romano, Giosafatto, Masi, & Mariniello, 2015). 353 
Pepsin secretion increases with postnatal age and is more immature in preterm 354 
infants(AC, 1991a).  355 
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In respect to intestinal digestion,  proteolysis in infants has similar pH and trypsin 356 
concentrations as those in the intestine of adults, whereas chymotrypsins and 357 
carboxypeptidases-B just account for about 10% to 60% of the activity found in 358 
adults(Edginton & Fotaki, 2010; Lebenthal & Lee, 1980).  Regarding lipid digestion, 359 
gastric lipase activity and output are similar in preterm(Roman, et al., 2007), full-term 360 
infants and adults(Armand, et al., 1996; Sarles, Moreau, & Verger, 1992). However, 361 
pancreatic lipases do vary between infants and adults with pancreatic triglyceride lipase 362 
(PTL) being the dominant intestinal lipolytic enzyme in adults while PTL-related protein 363 
2 and bile salt-stimulated lipase are the key lipases in infants(Lindquist & Hernell, 2010). 364 
In light of the high fat diet of infants(Hamosh, 2006), human breast milk contains 365 
endogenous lipase (bile salt-stimulated lipase mainly, 3.6-5.3 U/mL of milk) that 366 
compensates for the low amount of pancreatic lipases (5-10% the concentration found in 367 
adults) and low concentration of bile salts (50% of adult values)(Lebenthal, Lee, & 368 
Heitlinger, 1983). Regarding carbohydrate digestion, scarce data suggests low values of 369 
pancreatic amylase are found in the GI of infants aged less than 6 months. Thus, 370 
carbohydrate digestion in infants is believed to be highly facilitated by swallowed 371 
salivary α-amylase (at birth average of 10 % of the adult level but highly 372 
variable(Christian, Edwards, & Weaver, 1999; Sevenhuysen, Holodinsky, & Dawes, 373 
1984)) or mammary α-amylase. In addition, reports also indicate the infant GI performs 374 
carbohydrate digestion through lactase, sucrose-isomaltase and glucoamylase (with 375 
activities of ~50% above that of adults)(Bourlieu, et al., 2014; T. T. Nguyen, et al., 376 
2015a).  377 
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Another important step in infant GI maturation is colonic colonization of the infant gut 378 
with microbiota, which begins at birth and is an important player in the maturation and 379 
education of the immune system.  Development of the infant microbiota is characterized 380 
by rapid and large changes in microbial abundance, diversity and composition, until 381 
around 3 years of age when the microbiota becomes adult-like(Matamoros, Gras-Leguen, 382 
Le Vacon, Potel, & de La Cochetiere, 2013). Introduction of solid foods into the infant 383 
diet leads to a marked shift in microbial composition with an increase in clostridial 384 
species and a decrease in Bifidobacterium and Enterobacteriaceae. Many factors may 385 
influence the development of the gut microbiota in infants, such as mode of delivery, type 386 
of maternal diet, geographical location and consumption of antibiotics(Arrieta, Stiemsma, 387 
Amenyogbe, Brown, & Finlay, 2014). 388 
Based on the current physiological knowledge of the infant GI, various static and 389 
dynamic IVD models have been applied by researchers(Blanquet, et al., 2004; de 390 
Oliveira, et al., 2015; D. Dupont, et al., 2010; Roussel C, 2016; Shani-Levi, et al., 2013). 391 
Yet, the development of a harmonized static infant IVD is needed. One of the most 392 
formidable challenges in this respect is the clear definition of the consumer being 393 
recreated since digestive parameters are highly affected by gestational and postnatal age. 394 
For instance preterm newborns compared to full-terms of same age have higher gastric 395 
pH resulting from more frequent feeding, lower pepsin activity (10% of adult activity at 396 
four weeks vs. 30% in full-terms), faster gastric emptying, more limited gallbladder 397 
contraction index, lower concentration of electrolytes in pancreatic fluid, no amylase 398 
secretion and lower global pancreatic activity(Bourlieu, et al., 2014).  399 
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To date, several studies have depicted static infant IVD models applied for studying 400 
various aspects of protein and lipid digestion. These various models are summarized in 401 
Table 2. As can be noted, various discrepancies are found in these models and include 402 
discrepancies in gastric pH, ill-defined enzymatic proteolytic activity of enzymes and 403 
large variance in experimental duration. For example, the enzyme activity was most of 404 
the time not checked experimentally or based on the supplier’s general characteristics, 405 
which hampered experiment replication in other laboratory. After an estimation of the 406 
pepsin units per mL of milk, a very large range of values was observed, ranging from 4 to 407 
18563 U/mL of milk (Table 2). An in vivo study by Armand et al. (1996) reported an 408 
average postprandial value of 63 U/mL of gastric content/kg of bodyweight of preterm 409 
infants, which would correspond to 425 U/mL of milk for a term newborn of 4.25 kg and 410 
a meal to secretion ratio of 63:39 v/v(Armand, et al., 1996). In respect to the intestinal 411 
phase, pH was homogeneous (6.5 -7.5), but duration varied largely from 5 to 120 min and 412 
the meal proportion in the total volume varied from 25 up to 76 %. After an estimation of 413 
pancreatin content within each model, a factor of 30 between the maximum and the 414 
minimum values was found across models, which remains lower than that for pepsin (a 415 
4500 fold difference). Bile salts, arising from a porcine or bovine bile extract or from 416 
purified bile salts, were estimated to vary by a factor of 10 across models. 417 
In all models presented in Table 2, no clear definition of the infant stage was given, 418 
except for Fogleman et al. (2012)(Fogleman, Cohen, Sakamoto, & Allen, 2012), who 419 
aimed to mimic preterm infant digestion. Further, there are some dynamic IVD models 420 
described in recent literature(Blanquet, et al., 2004; Ménard, et al., 1995; Menard, et al., 421 
2014; Shani-Levi, et al., 2013) ,(de Oliveira, et al., 2015; Havenaar, et al., 2013; Roussel 422 
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C, 2016). In essence, these models try to recreate some of the dynamic aspects of 423 
digestion, e.g. gastric pH profiles post meal ingestion and gastric emptying rates. One of 424 
these has even been validated against in vivo data of proteolysis kinetics obtained in 425 
piglets(Menard, et al., 2014). The TIM model developed by TNO (Netherlands) was 426 
adapted to simulate the GI of newborns, infants and toddlers (0–1, 1–6, and 6–24 months 427 
of age, respectively) after ingestion of various types of food (formula milk, milk and 428 
cereals) and validated for these three age groups against published pharmacokinetic data 429 
on paracetamol(Havenaar, et al., 2013). However, in this study, not all GI parameters 430 
applied to this commercial IVD model have been made publicly available. The same 431 
model has been very recently adapted to mimic, based on in vivo data, the gastric and 432 
small intestinal conditions of infant from 6 months to 2 years(Roussel C, 2016). Some 433 
dynamic colonic models have also been developed(C Cinquin, Le Blay, Fliss, & Lacroix, 434 
2004; Cécile Cinquin, Le Blay, Fliss, & Lacroix, 2006a, 2006b). The composition and 435 
diversity of the bacterial community, as well as its metabolism, was found to be well 436 
correlated with those found in vivo in infant feces.  437 
Altogether, infant IVD models are increasing in their applicability to food research, 438 
however, the variances and discrepancies found in current infant IVD model call for 439 
future efforts to better define a simple, harmonized and consensus infant static IVD 440 
model, such as that obtained for an adult IVD model(Minekus, et al., 2014) as well as 441 
sophisticated dynamic IVD models. All of these should be developed with a rationale 442 
similar to that applied by the infant formula industry, i.e. focusing on specific and defined 443 
target populations such as stage one for 0-3 months, stage 2 for 3-6 months etc.  444 
3.2. Elderly 445 
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Elderly nutrition, pharmacology and overall health care have been identified as one of the 446 
rising global challenges(UN, 2013). Ageing is typically accompanied by a milieu of 447 
changes including substantiated alterations and deterioration of gut functions, such as 448 
secretion of digestive fluids and enzymes, saliva, GIT contractions and chyme passage 449 
rates(Di Francesco, et al., 2005; Feldman, Cryer, McArthur, Huet, & Lee, 1996; Laugier, 450 
Bernard, Berthezene, & Dupuy, 1991; Nagler & Hershkovich, 2005; Russell, et al., 1993; 451 
Salles, 2007; Vellas, et al., 1988). Due to the irreversible nature of the changes in GIT 452 
functions, there is a growing need to deepen our understanding of foods' digestive fate in 453 
the elderly GI. This would facilitate rational design of foods to accommodate elderly 454 
physiological capabilities, improve nutrient bioaccessibility and bioavailability and help 455 
combat elderly malnutrition. Despite comprehensive knowledge on the GI deterioration 456 
with age and its ramifications to elderly malnutrition(Remond, et al., 2015), there are 457 
scant IVD models of the elderly GI found in literature. One most recent study assessed 458 
the antioxidant capacity of a milk protein matrix in aged women, both in vitro and in 459 
vivo(Power-Grant, et al., 2016). However, the target population of the study focused 460 
solely on women in the ages of 50-70. In relation to IVD models recreating elderly 461 
digestive conditions, two recent studies have been identified to apply in vivo data to the 462 
modeling parameters (Denis, et al., 2016; Levi & Lesmes, 2014).  The first reports the 463 
set-up of a dynamic gastro-intestinal elderly (> 70 years old) model based on commercial 464 
bioreactors with details on all the parameters used and the rationale of their 465 
selection(Levi & Lesmes, 2014). The second, reports an adaptation of the TNO 466 
gastrointestinal model (TIM) to the specific digestive conditions of the elderly (> 65 467 
years old) and is used to study meat protein dynamic digestion(Denis, et al., 2016). A 468 
21 
 
summary of the digestive conditions applied in these models are given in Figure 2, also 469 
summarizes conditions of the elderly population at the colon. Similar to the field of infant 470 
IVD modelling, elderly digestion models require not only harmonization but also 471 
validation and clearer definition of the elderly being studied.  472 
3.3. Developing IVDs for humans with GI disorders   473 
In light of the centrality of the GI system in human health and disease, various studies 474 
present information on human GI disorders. These are defined as diseases and/or 475 
conditions that interfere with the intake, digestion, and/or absorption of nutrients, causing 476 
various clinical symptoms and are broadly defined as maldigestion. Physiologically, the 477 
spectrum and underlying causes of GI disorders is immense from such conditions causing 478 
discomfort (e.g. lactose malabsorption) to those compromising health (e.g. pancreatic 479 
insufficiency in cystic fibrosis patients). All in all, these conditions arise from altered GI 480 
functions which lead to various effects on the disintegration, breakdown and uptake of 481 
nutrients and consequently on health(Högenhauer, 2010). Some common factors that 482 
interfere with food digestion and related disorders, infections and surgical procedures 483 
linked to them are summarized in Table 3. In respect to food breakdown and 484 
bioaccessibility, many of the situations described may be mirrored using IVD models, as 485 
such conditions have been found to arise from variance and abnormalities in digestive 486 
parameters such as changes in gastric/intestinal pH, secretion of digestive juices and 487 
transit times. Other disorders such as food allergies, autoimmune disorders (celiac sprue), 488 
Crohn’s disease, obesity or diabetes are linked to interferences with the absorption and/or 489 
metabolism of nutrients from the food(Nolan, Johnston, & Walters, 2012), hence IVD 490 
models for such conditions require much more sophistication in their in vitro recreation, 491 
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if at all feasible. Yet, efforts to develop IVD models for specific strata of the population 492 
would offer useful tools not only in the development of new tailored foods but also 493 
improving relevant nutritional guidelines.  494 
One example for such a potential novel IVD model is for the community of  Cystic 495 
Fibrosis (CF) patients that has over 35,000 cases registered in Europe(Colombo & 496 
Littlewood, 2011). At least 85% of CF patients have pancreatic insufficiency of lipases, 497 
resulting in fat malabsorption and binding patients to the use of pancreatic enzyme 498 
supplements. Armand et al. (2004) studied the effect of diet on gastric lipase levels and 499 
fat digestion in children with CF and reported that gastric lipase was high in cystic 500 
fibrosis patients maintained on fat-rich diets(Armand, et al., 2004). Further, Gelfond et al. 501 
(2013) measured the intestinal pH and GI transit profiles in CF patients(Gelfond, Ma, 502 
Semler, & Borowitz, 2013). Based on this and other in vivo reports, the development of 503 
an IVD model of a CF patient need to focus on the unique secretion of pancreatic fluid 504 
and bile, both critical parameters in lipid digestion. Analytical studies show a 3.8-fold 505 
higher content of glycoconjugates than tauroconjugates in human aspirates(Brodlie, et al., 506 
2015). Thus, artificial bile should reflect composition and imbalances between tauro- and 507 
glycol-conjugates isomers and bile concentration should be low to reflect the decreased 508 
bile secretion (1mM). In respect to enzymatic activity, CF patients are pancreatic 509 
insufficient when pancreas function is below 10% than that of a healthy adult. Then, the 510 
pancreatine activity in a CF model should be 10-fold lower than that considered in 511 
healthy adults.  512 
Another potential IVD model to be developed is that of Gastric Bypass (GBP) patients 513 
(bariatric surgery patients). GBP surgery is one of the most common and effective 514 
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treatments for morbid obesity but can also be used to address conditions such as type 2 515 
diabetes or hypertension. Available physiological literature data on the digestive process 516 
are limited to indirect, with postprandial serum or urine measurements or scintigraphy 517 
evaluation of gastric emptying. Gastric emptying is reported to be very rapid for liquids, 518 
based on D-xylose in serum, from 18.6±6.9 min prior to GBP to 7.9±2.7 min after 519 
GBP(Wang, et al., 2012). Extremely rapid pouch emptying was reported for water vs. 520 
whey proteins vs. olive oil as preloads (30 min) for a liquid glucose drink (t50 3.8±0.9 vs. 521 
4.1±0.6 vs. 3.6±0.5 min, respectively) and for a solid beef patty meal (1.6±0.7 vs. 1.1±0.6 522 
vs. 1.3±0.5 min, respectively) (N. Q. Nguyen, et al., 2016). Bojsen-Moller et al. (2015) 523 
(Bojsen-Moller, et al., 2015) observed accelerated caseinate digestion and amino acid 524 
absorption (C13 leucine), resulting in faster and higher but more transient postprandial 525 
elevation of plasma amino acids. Overall, the incidence of a dumping syndrome, defined 526 
as a rapid gastric emptying, is also elevated after GBP(Horowitz, Collins, Harding, & 527 
Shearman, 1985).  528 
Sleeve Gastrectomy (SG), whereby the stomach duodenum connection remains intact but 529 
the volume of the stomach is drastically reduced, has been also been used as an option for 530 
surgical treatment of obesity. In such patients, gastric emptying half times (t50) were 531 
reported to be drastically reduced for both liquids and solids food (SG vs. control group: 532 
34.9±24.6 vs. 13.6±11.9 min for water and 78±15.01 vs. 38.3±18.77 min for solids [egg 533 
sandwich])(Horowitz, et al., 1985). The growing body of evidence on the ramifications of 534 
GBP procedures on GI function could enable the development of a relevant IVD model. 535 
Such a model would require a short gastric phase between 30 and 60 minutes, probably 536 
coupled with a higher pH of 3.5-4.0 compared to the pH 3.0 used in an adult IVD model. 537 
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However, without luminal data, only estimates are possible. Yet, a comprehensive effort 538 
should be done to mine the literature or conduct in vivo experiments to determine 539 
enzymatic activity of pepsin and pancreatic enzymes as well as bile compositions.    540 
The examples of CF and GBP patients are only two possibilities for novel IVD models 541 
that can be developed and subsequently validated. Other GI conditions and abnormalities 542 
can be recreated in IVD models pending relevant in vivo data is collected or found in 543 
scientific literature. These stress out the potential of expanding the horizons of IVD 544 
models based on the rationale exploitation of medical research.  545 
4. Conclusion 546 
The current modern food production system is complex, dynamic and constantly strives 547 
to fabricate safe and nutritious food products and solutions. Amongst the various efforts, 548 
researchers and manufacturers seek to rationally process, structure and formulate foods 549 
towards healthier outcomes for the consumer. These include development of food 550 
delivery systems for protection of bioactives ingredients added to food, controlling and 551 
targeting their release in the human gastrointestinal tract and affecting various dimensions 552 
of consumer well-being, e.g. shaping the colon microbiome or inducing satiety and 553 
satiation. All of these efforts rely on understanding the underlying principles guiding 554 
food's digestive fate. An understanding, which can be significantly advanced thanks to 555 
the soaring number of studies using in vitro and in vivo digestion models.  556 
As part of the food-health revolution and evolution of food manufacturing towards 557 
tailored and personalized foods, the potential of IVD models could be maximized when 558 
extended to recreate various strata of the human population. The development of IVD 559 
models should rely on better and extensive understanding of in vivo digestion conditions 560 
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in different groups of the population but would offer better opportunities to develop 561 
relevant products with high bioefficacy. Evidently, such novel tools for food and 562 
nutritional research would necessitate adequate standardization and validation to ensure 563 
synchronization of efforts and success. Such efforts would also greatly benefit from the 564 
deposition and gathering of relevant information in a database where food and health care 565 
professionals could upload in vivo data or in vivo in vitro correlations and put together 566 
pieces of puzzles needed in the development of new IVD models. In light of the concern 567 
over rising prevalence of chronic diseases and challenges in feeding the world, nutritional 568 
management of health and disease prevention are challenges at the footsteps of dedicated 569 
professionals. The authors of this paper hope that it will stimulate relevant progress in the 570 
field and help orchestrate global efforts towards the shared goal of advancing food 571 
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Table and Figure Captions 579 
Table 1. Physiological characterization of human gastro-intestinal fluids. 580 
 581 
Table 2. Literature review of the proposed in vitro static models for infant gastro-582 
intestinal digestion. 583 
 584 
Table 3. Factors interfering with food digestion and related disorders. 585 
 586 
Figure 1. Summary of the developing digestive physiology in the human infant. HGL- 587 
Human Gastric Lipase, PTL- pancreatic triglyceride lipase, BSSL-bile salt-stimulated 588 
lipase, PTLRP2- pancreatic triglyceride lipase-related protein 2. 589 
 590 
Figure 2. Summary of the developing digestive physiology in the elderly. 591 
  592 
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Table and Figure  593 
Table 1 594 





Fluid output  
Transit time of meal 
 




7 ; 7.4-7.6 
10 mL per meal 
10 sec – 2 min 
 
Guyton A.C. 1991(AC, 1991a)  
Versantvoorf C.H.M.  2004(C. 
H. M. Versantvoort, Oomen, 
Van de Kamp, Rompelberg, & 
Sips, 2005) 





Transit time of meal 
 
1.5 - 2.0 




3.0 – 7.0 
 
15 min – 3 hours 
 
Dressman J.B.1986(Dressman, 
et al., 1990) 
Sams L. 2016(Sams, et al., 
2016) 
Guerra A. 2012(Guerra, et al., 
2012) 
Small intestine                                                                              
pH 
Bicarbonate secretion 




Total proteolytic activity   
Trypsin Output activity 
 
Chymotrypsin Output activity  
 
 






































50-100-500 U/mL              
33-77 IU/mL 

















Dressman JB. 1990(Dressman, 
et al., 1990) 
Ekmekcioglu C. 
2002(Ekmekcioglu, 2002) 
Ulleberg E. 2011(Ulleberg, et 




Bacterial load  
 
Short chain fatty acids  






1x1011-1012  CFU/g 










a Taurodeoxycholate; b Glycocholate; c Glycochenodeoxycholate; d Glycodeoxycholate 595 
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Table 2 596 
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60 99 : 1 supernatant of 
gastric juice from 2 
neonates 














6.5 30  76 : 24 Porcine 
trypsin :  




















7 120 40 : 60 Pancreatin :  
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7 120 25 : 75   Pancreatin : 





  599 
Refs Meal Gastric phase Intestinal phase 
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4.5 35  15 : 9  - 0.013 
mg/ml 
of milk 
4.0 0.0001 7.5 120 15 : 20 Porcine 
pancreatin :  
9 mg/mL of 
SDF 












As detailed for Dupont et al., 2010 








3 60 50 : 50  - 113.8 
U/ml of 
SGF 
113.8 0.0008 6.5 60 25 : 75   Bovine 
trypsin : 8.6 




Table 3 600 
Causes of maldigestion Related diseases  Impact 
Digestive enzyme 
deficiency 







Hydrolysis of proteins, 
carbohydrates and fats 
Digestive enzyme 
inactivation by excess of 
HCl 
Zollinger-Ellison syndrome 
Dissynchrony of enzyme 
release and inadequate 
mixing 
Hyperthyroidism, post 
billroth ii procedure 
(gastrojejunostomy), 
gastric bypass 




Fat soluble vitamins 
absorbtion 
Impared bile secretion Cystic fibrosis,  chronic 
cholestasis 
Increased bile salt loss Ileal disease or resection 
Bile salt de-conjugation Bacterial: overgrowth 
Bacterial consumption of 
nutrients 
Bacterial overgrowth 




Bioavailability of specific 
nutrients Reduced gastric acid  Atrophic gastritis 
associated to B12 
deficiency 
Reduced intrinsic factor Pernicious anemia 
associated to B12 
deficiency 
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